Related Experiment Video
Updated: Jun 5, 2025
Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
Published on: September 20, 2024
Bivalent Boosters and Risk of Postacute Sequelae Following Vaccine-Breakthrough SARS-CoV-2 Omicron Infection: A
Liang En Wee1,2,3, Jue Tao Lim1,4, Mayank Goel1
1National Centre for Infectious Diseases, Singapore, Singapore.
Background:
Vaccination has been shown to attenuate the risk of postacute sequelae following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, no prior population-based studies have evaluated if updated bivalent boosters reduce risk of postacute sequelae following Omicron variant infection, versus ancestral vaccines.
Methods:
National databases were utilized to construct a population-based cohort of adult individuals infected during Omicron-predominant transmission. Risk and excess burden (EB) of prespecified multiorgan new-incident diagnoses at 31-365 days post-SARS-CoV-2 infection were compared between individuals who received prior bivalent boosters and those boosted with ancestral messenger RNA (mRNA) vaccines, using competing-risks regression.
Results:
A total of 1 080 348 vaccine-breakthrough infections after an ancestral mRNA booster were contrasted against 9824 vaccine-breakthrough infections following a bivalent mRNA booster. There was an estimated 37.8% (hazard ratio [HR], 0.62 [95 confidence interval {CI}, .53-.73]) decrease in risk and lower overall EB per 1000 (-28.73 [95% CI, -40.47 to -16.99]) of any postacute sequelae, as well as a 39.9% (HR, 0.62 [95% CI, .52-.73]) decrease in risk and lower EB (-22.95 [95% CI, -32.71 to -13.19]) of any postacute neurological sequelae, among individuals who received prior bivalent boosters, versus those boosted with ancestral mRNA vaccines. Specifically, there was reduced risk of thrombotic disorders (HR, 0.54 [95% CI, .29-.99]), episodic neurological disorders (HR, 0.55 [95% CI, .43-.72]), movement disorders (HR, 0.57 [95% CI, .47-.70]), and autoimmune vasculitis (HR, 0.54 [95% CI, .29-.99]) 31-365 days postinfection among those who received prior bivalent boosters, versus those boosted with ancestral mRNA vaccines.
Conclusions:
Boosting with updated bivalent mRNA vaccines was associated with greater attenuation of risk for postacute sequelae following Omicron variant infection, compared with ancestral mRNA boosters.
Related Concept Videos
01:51Vaccinations
01:23Immunological Memory
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
00:42Cross-reactivity
00:57Viral Recombination
01:30Acute Pharyngitis
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...